[Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation].
Congenital Myasthenic Syndromes (CMS) are a heterogeneous group of diseases caused by genetic defects affecting neuromuscular transmission. The twenty five past Years saw major advances in identifying different types of CMS due to abnormal presynaptic, synaptic, and postsynaptic proteins. CMS diagnosis requires two steps: 1) positive diagnosis supported by myasthenic signs beginning in neonatal period, efficacy of anticholinesterase medications, positive family history, negative tests for anti-acetylcholine receptor (AChR) antibodies, electromyographic studies (decremental response at low frequency, repetitive CMAP after one single stimulation); 2) pathophysiological characterisation of CMS implying specific studies: light and electron microscopic analysis of endplate (EP) morphology, estimation of the number of AChR per EP, acetylcholinesterase (AChE) expression, molecular genetic analysis. Most CMS are postsynaptic due to mutations in the AChR subunits genes that alter the kinetic properties or decrease the expression of AChR. The kinetic mutations increase or decrease the synaptic response to ACh resulting respectively in Slow Channel Syndrome (characterized by a autosomal dominant transmission, repetitive CMAP, refractoriness to anticholinesterase medication) and fast channel, recessively transmitted. AChR deficiency without kinetic abnormalities is caused by recessive mutations in AChR genes (mostly epsilon subunit) or by primary rapsyn deficiency, a post synaptic protein involved in AChR concentration. Recently, mutations in SCN4A sodium channel have been reported in one patient. AChE deficiency is identified on the following data: recessive transmission, presence of repetitive CMAP, refractoriness to cholinesterase inhibitors, slow pupillary response to light and absent expression of the enzyme at EP. This synaptic CMS is caused by mutations in the collagenic tail subunit (ColQ) that anchors the catalytic subunits in the synaptic basal lamina. The most frequent presynaptic CMS is caused by mutations of choline acetyltransferase. Several CMS are still not characterized. Many EP molecules are potential etiological candidates. In these unidentified cases, other methods of investigations are required: linkage analysis, when sufficient number of informative relatives are available, microelectrophysiological studies performed in intercostal or anconeus muscles. Prognosis of CMS, depending on severity and evolution of symptoms, is difficult to assess, and it cannot not be simply derived from mutation identification. Most patients respond favourably to anticholinesterase medications or to 3,4 DAP which is effective not only in presynaptic but also in postsynaptic CMS. Specific therapies for slow channel CMS are quinidine and fluoxetine that normalize the prolonged opening episodes. Clinical benefits derived from the full characterisation of each case include genetic counselling and specific therapy.
Andreux
F
F
INSERM 582 et Institut de Myologie, Hôpital de la Pitié-Salpêtrière.
Hantaï
D
D
Eymard
B
B
D000109:Acetylcholine / Q000378:metabolism; D000110:Acetylcholinesterase / Q000172:deficiency / Q000235:genetics; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003943:Diagnostic Techniques, Neurological; D018740:Genetic Heterogeneity; D005821:Genetic Techniques; D006801:Humans; D007381:Intermediate Filament Proteins / Q000172:deficiency / Q000235:genetics; D015640:Ion Channel Gating / Q000187:drug effects; D020294:Myasthenic Syndromes, Congenital / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D062553:NAV1.4 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins / Q000235:genetics; D009469:Neuromuscular Junction / Q000503:physiopathology; D010641:Phenotype; D051190:Plectin; D011950:Receptors, Cholinergic / Q000032:analysis / Q000172:deficiency / Q000235:genetics; D015222:Sodium Channels / Q000172:deficiency / Q000235:genetics; D009435:Synaptic Transmission
D002800:Cholinesterase Inhibitors; D007381:Intermediate Filament Proteins; D062553:NAV1.4 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins; C495332:PLEC protein, human; D051190:Plectin; D011950:Receptors, Cholinergic; C106251:SCN4A protein, human; D015222:Sodium Channels; D000110:Acetylcholinesterase; D000109:Acetylcholine